TPST Stock Summary and Trading Ideas (Tempest Therapeutics | NASDAQ:TPST)

Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.

Tempest Therapeutics trades on the NASDAQ stock market under the symbol TPST.

As of September 8, 2026, TPST stock price declined to $0.99 with 186,941 million shares trading.

TPST has a beta of 2.72, meaning it tends to be more sensitive to market movements. TPST has a correlation of 0.09 to the broad based SPY ETF.

TPST has a market cap of $16.33 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, TPST traded as high as $127.01 and as low as $.84.

The top ETF exchange traded funds that TPST belongs to (by Net Assets): VXF, VTI.

TPST has underperformed the market in the last year with a price return of -90.9% while the SPY ETF gained +19.2%. TPST has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -22.3% and -11.1%, respectively, while the SPY returned +3.9% and 0.0%, respectively.

TPST support price is $.98 and resistance is $1.09 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TPST shares will trade within this expected range on the day.